A career in Oncology, endless possibilities
GSK Oncology has a commitment to the discovery and development of new oncology therapies with the life-changing potential of helping patients with cancer, specifically in three areas of cancer research: Cancer Epigenetics, Immuno-Oncology, and Oncology Cell Therapy. We have a need to recruit professionals to fill a variety of roles.
Join us in Oncology to help improve the lives of patients around the world. We have vacancies in the U.S., U.K. and mainland Europe.
If you are an expert in one of the fields below, we have a role for you. Our vacancies regularly include opportunities for:
|Commercial Insights & Analytics||Medical Information|
|Communications||Medical Science Liaisons|
|Finance||Physicians (Drug Development & Medical Affairs)|
|Health Economics & Outcomes Research||Scientific Directors (Drug Development & Medical Affairs)|
|Marketing & Sales||Regulatory Affairs|
As a science-led, global healthcare business with clear values, we offer countless opportunities for people at various stages of their careers. On-the-job learning and rewarding individual contributions are extremely important to us. We believe in creating an inclusive and safe working environment and supporting our employees to help their communities.
We focus on creating an inclusive organization where all employees feel engaged and know their work makes an important contribution. An inclusive environment welcomes different knowledge, perspectives, experiences and working styles from across our global population. This not only enhances individual creativity and innovation but makes good business sense.
See what we’re doing in Oncology
GSK to acquire TESARO
GSK recently announced an agreement to acquire TESARO, an oncology focused company based in the US. The proposed transaction will strengthen our pharmaceutical business, accelerating the build of our pipeline and commercial capability in oncology.
A new approach to R&D at GSK
Hal Barron, Chief Scientific Officer and President, R&D, presented our R&D update at Q2 results in July 2018.